Summary
Signal counts
Assets tracked: 3
Watchlist assets: 3
Registry stop assets: 2
Sponsor overview
Assistance Publique - Hôpitaux de Paris
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT06152523 | https://clinicaltrials.gov/study/NCT05580861 | https://clinicaltrials.gov/study/NCT01215578
Assets
Linked programs
- Monalizumab/MEDI5257: Registry Stop Signal (4/5)
- Sulfasalazine: Timeline Staleness Signal (2/5)
- Sutent: Registry Stop Signal (4/5)